Skip to main content
Kodiak Sciences Inc. logo

Kodiak Sciences Inc. — Investor Relations & Filings

Ticker · KOD ISIN · US50015M1099 LEI · 254900IXI5NI8C9OQE24 US Manufacturing
Filings indexed 383 across all filing types
Latest filing 2019-12-04 Regulatory Filings
Country US United States of America
Listing US KOD

About Kodiak Sciences Inc.

https://kodiak.com/

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing therapeutics for chronic, high-prevalence retinal diseases. The company's mission is to address the leading causes of blindness, such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. Its core technology is the proprietary Antibody Biopolymer Conjugate Drug (ABCD) Platform, which is designed to create long-acting biologics with enhanced durability, potentially reducing treatment frequency for patients. Kodiak's late-stage clinical pipeline includes its lead candidate, tarcocimab tedromer, an anti-VEGF therapy, as well as other candidates targeting retinal vascular diseases and macular edema.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2019-12-04 English
424B3
Prospectus
2019-12-04 English
424B3
Prospectus
2019-12-03 English
8-K
Regulatory Filings
2019-12-02 English
8-K
Regulatory Filings
2019-11-20 English
Regulatory Filings 2019
Regulatory Filings
2019-11-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.